Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Topics:
Pediatric Oncology
•
Medical Oncology
•
AYA
•
Hematology
•
Pediatric Hematology
•
Benign Hematology
•
Endocrinology
How do you monitor risk of erythrocytosis from testosterone use for female to male transgender patients?
Related Questions
For patients with incidental findings of venous thromboembolism during workup of a treatable malignancy, how do you approach discontinuation after the treatment is complete?
For T cell ALL treated in CR (without transplant), how often do you do BM biopsies as part of surveillance, and for how long?
In a young female with severe osteoporosis due to congenital estrogen deficiency, can estrogen be prescribed if genetic testing for congenital disorders reveals a heterozygous Factor V Leiden mutation?
Would you consider TPO mimetics for chemotherapy induced thrombocytopenia that persists despite dose reductions?
How should elevated PT of unclear etiology and significance be evaluated?
What is your surveillance protocol for patients with common variable immunodeficiency receiving chronic IVIG therapy?
How do you approach an ITP patient who responds very well to steroids but the response is short-lived?
Do you repeat images in patients with venous thrombosis to inform decision about duration of anticoagulation?
How do you mitigate 6-MP-induced GI toxicity in pediatric and AYA patients with leukemia?
How do you counsel patients with transfusion dependent beta thalassemia about luspatercept?